Potassium Phosphate, Monobasic Potassium Phosphate, Dibasic Injection, has 6 known drug interactions based on U.S. FDA drug labeling data. Of these, 6 are contraindicated combinations that should be avoided entirely. Notable interactions include combinations with Angiotensin Ii, Cyclosporine, Digoxin. Patients taking Potassium Phosphate, Monobasic Potassium Phosphate, Dibasic Injection, should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 6
- Contraindicated
- 6
Contraindicated (6)
- Potassium Phosphate, Monobasic Potassium Phosphate, Dibasic Injection, + Angiotensin Ii— Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor s…
- Potassium Phosphate, Monobasic Potassium Phosphate, Dibasic Injection, + Cyclosporine— Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor s…
- Potassium Phosphate, Monobasic Potassium Phosphate, Dibasic Injection, + Digoxin— Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor s…
- Potassium Phosphate, Monobasic Potassium Phosphate, Dibasic Injection, + Mao Inhibitors— Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor s…
- Potassium Phosphate, Monobasic Potassium Phosphate, Dibasic Injection, + Potassium Supplements— Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor s…
- Potassium Phosphate, Monobasic Potassium Phosphate, Dibasic Injection, + Tacrolimus— Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor s…